panel-2-ip-deal-making-in-life-sciences
27 May 2026VideosRegulation & IndustryJohn Rearick, Cooley | Sarah Hogan, Cooley | Mark Shtilerman, Deerfield Management | Jennifer Burdman, Sauvegarder Investment Management | Kumar Govindaswamy, Kymera Therapeutics

WATCH: IP deal-making in life sciences—valuation, due diligence, and transaction strategies

Structuring successful IP transactions in the life sciences sector requires rigorous due diligence and sophisticated valuation models. This panel brings together deal-makers and valuation experts to share strategies for protecting value and enabling innovation in complex M&A and licensing deals.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Regulation & Industry
5 November 2026   Things can go “sideways pretty quickly” if the two sides of pharma protection are not communicating with each other, said a senior panel of industry counsel at LSPN Fall.
Regulation & Industry
5 November 2026   From November 1, oral proceedings before a Board of Appeal can be audio-recorded and transcribed using artificial intelligence, but any material generated will be kept internal and will not form part of the file or be made available
Regulation & Industry
30 October 2026   With its goal of becoming a global life sciences leader still some way off, the UK is betting on new investment, AI and regulatory changes to help close the gap, according to the government’s autumn budget.